Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
A small, randomised pilot trial finds that nabiximols can be safely delivered to nursing home residents with Alzheimer’s-related agitation, achieving perfect adherence and zero adverse drug reactions, but pandemic-disrupted recruitment and a sample of only 29 participants leave questions of clinical effectiveness entirely unanswered.
Why This Matters
Agitation is one of the most distressing and clinically difficult symptoms in Alzheimer’s dementia, driving caregiver burden, early institutionalization, and inappropriate prescribing of antipsychotics with well-documented harms in older adults. No existing pharmacological treatment is fully satisfactory for this population, and the therapeutic landscape remains largely unchanged in decades. A cannabinoid formulation already licensed for other indications that could be safely administered in care homes would represent a genuinely novel therapeutic avenue, but only if the basic question of deliverability is answered first. That is what this study set out to test.
Clinical Summary
Agitation in Alzheimer’s dementia affects a substantial proportion of nursing home residents and is associated with accelerated cognitive decline, reduced quality of life, and significant distress for patients and caregivers alike. The STAND trial, published in Age and Ageing in 2025 by Brooke and colleagues, was a randomised, double-blind, placebo-controlled feasibility study designed to determine whether nabiximols (Sativex), an oromucosal spray containing THC and CBD, could be safely and practically delivered to this population. The mechanistic rationale rests on endocannabinoid system modulation: cannabinoid receptors in the central nervous system are implicated in neuroinflammation, anxiety regulation, and behavioral control, and preclinical evidence suggests cannabinoid signaling may be altered in Alzheimer’s pathology.
Of 53 individuals assessed for eligibility across greater London nursing homes, 29 were randomised, well below the pre-specified target of 60 needed to meet formal feasibility criteria. Notably, all 29 participants completed the 8-week study with 100% adherence and zero adverse drug reactions. However, the recruitment shortfall, attributable in large part to COVID-19 pandemic disruptions during the 2021 to 2022 enrollment window, means the study technically did not satisfy its own primary feasibility benchmark. Preliminary effect size estimates on the Cohen-Mansfield Agitation Inventory were generated per protocol but are explicitly unpowered and cannot be interpreted as evidence of efficacy. The authors appropriately conclude that a larger, adequately powered phase 3 confirmatory trial is the necessary next step before any clinical recommendations can be made.
Dr. Caplan’s Take
What this study gets right is asking the unglamorous but essential first question: can we actually deliver this intervention safely to frail nursing home residents with advanced dementia? The answer appears to be yes, and that is not trivial. Zero adverse reactions and perfect adherence in a population where medication administration is notoriously difficult tells us something genuinely useful. But patients and families who ask me about cannabis for Alzheimer’s agitation are not asking whether a trial can be run. They want to know if it works, and this study cannot answer that question. An honest response requires being clear about that gap.
In practice, I do not recommend nabiximols or other cannabinoid formulations for Alzheimer’s agitation based on current evidence. What I do emphasize is a structured approach to behavioral symptoms: identifying and addressing unmet needs, environmental modifications, and non-pharmacological interventions as first-line strategies, with pharmacological options reserved for cases where distress is significant and refractory. I follow this space closely because the therapeutic need is real, but the evidence is not there yet.
Clinical Perspective
This study sits at the very beginning of the clinical research arc for nabiximols in Alzheimer’s agitation. It confirms that oromucosal cannabinoid delivery is logistically viable in care homes and that safety signals in this specific population do not appear prohibitive at the doses studied, which is information that was genuinely uncertain before this trial. It does not, however, confirm, challenge, or resolve any questions about therapeutic effectiveness. Clinicians should be aware that preliminary effect size data included in the paper were generated per protocol for planning purposes only and carry no inferential weight. No patient-facing recommendation regarding nabiximols for agitation can be supported by this evidence.
From a pharmacological standpoint, nabiximols delivers both THC and CBD, and clinicians should note the potential for cannabinoid interactions with commonly prescribed medications in this population, including sedatives, antipsychotics, and drugs metabolized through CYP3A4 and CYP2C19 pathways. Falls risk in frail older adults exposed to any centrally acting agent remains a standing concern. The single most actionable takeaway for clinicians right now is to document and monitor agitation using validated instruments like the Cohen-Mansfield Agitation Inventory in routine care, which both improves symptom management today and positions patients for appropriate enrollment in future confirmatory trials when they become available.
Study at a Glance
- Study Type
- Randomised, double-blind, placebo-controlled parallel-group feasibility trial
- Population
- Adults aged 55 to 95 with probable Alzheimer’s dementia and clinically significant agitation, residing in UK nursing homes
- Intervention
- Nabiximols oromucosal spray (maximum 4 sprays per day; 10.8 mg THC and 10 mg CBD), titrated over a 4-week treatment course
- Comparator
- Matching placebo spray
- Primary Outcomes
- Pre-specified feasibility criteria: enrollment of 60 or more participants, 75% or greater follow-up at 4 weeks, 80% or greater adherence, and Cohen-Mansfield Agitation Inventory effect size of 0.3 or greater
- Sample Size
- 29 randomised (target was 60)
- Journal
- Age and Ageing
- Year
- 2025
- Registration
- ISRCTN71635621
- Funding Source
- Not specified in available analysis
What Kind of Evidence Is This
This is a published primary randomised controlled trial report, but one designed and registered explicitly as a feasibility study rather than an efficacy trial. It sits in the lower portion of the interventional evidence hierarchy, providing logistical, safety, and tolerability data to inform the design of a future confirmatory trial. The single most important inference constraint is that no conclusion about whether nabiximols reduces agitation in Alzheimer’s patients can be drawn from this study, regardless of any numerical trends in outcome measures.
How This Fits With the Broader Literature
The broader literature on cannabinoids for neuropsychiatric symptoms in dementia remains sparse and inconclusive. Prior small studies of dronabinol and nabilone in dementia-related agitation have produced mixed results with significant methodological limitations, and no large confirmatory trial has been completed for any cannabinoid formulation in this indication. The STAND trial extends this literature primarily by demonstrating that a specific delivery mechanism, oromucosal spray, is feasible in a care home setting with advanced dementia patients, a population typically excluded from or poorly represented in cannabinoid research. It does not resolve the fundamental uncertainty about whether endocannabinoid modulation produces clinically meaningful behavioral improvement in Alzheimer’s disease.
Common Misreadings
The most likely overinterpretation is treating the zero adverse reactions and perfect adherence as evidence that nabiximols “works” for Alzheimer’s agitation or is “promising” in a way that implies therapeutic benefit. Safety and deliverability are necessary but entirely insufficient conditions for clinical adoption. Similarly, any preliminary effect size estimates reported in the paper exist solely to inform power calculations for a future trial and should not be cited as evidence of a treatment signal. The recruitment shortfall also means that even the feasibility conclusions carry important caveats, as the study did not meet its own pre-specified threshold for declaring the trial design fully feasible.
Bottom Line
The STAND trial establishes that nabiximols can be safely and practically administered to nursing home residents with Alzheimer’s agitation, with encouraging tolerability and adherence data. It does not establish, suggest, or approximate evidence that nabiximols is effective for this condition. A larger, adequately powered phase 3 trial is the clearly defined next step. Until such a trial is completed and reported, there is no evidence base to support clinical use of nabiximols for dementia-related agitation.
References
- Brooke J, et al. Nabiximols for agitation in Alzheimer’s disease in nursing homes (STAND): a randomised, double-blind, placebo-controlled feasibility trial. Age and Ageing. 2025. ISRCTN71635621.
Have thoughts on this? Share it:
